DK3270909T3 - Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko - Google Patents

Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko Download PDF

Info

Publication number: DK3270909T3
Authority: DK; Denmark
Prior art keywords: etc1002; statins; reduction; treatment; fixed
Prior art date: 2015-03-16

Application number

DK16765682.6T

Other languages

English (en)

Inventor

Roger Schofield Newton

Noah Laban Rosenberg

Diane Elaine Macdougall

Original Assignee

Esperion Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-16

Filing date

2016-03-16

Publication date

2024-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56919968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3270909(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-16 Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc

2024-01-29 Application granted granted Critical

2024-01-29 Publication of DK3270909T3 publication Critical patent/DK3270909T3/da

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
HYHMLYSLQUKXKP-UHFFFAOYSA-N bempedoic acid Chemical compound OC(=O)C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(O)=O HYHMLYSLQUKXKP-UHFFFAOYSA-N 0.000 title 1
229940000425 combination drug Drugs 0.000 title 1
230000002526 effect on cardiovascular system Effects 0.000 title 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)

DK16765682.6T 2015-03-16 2016-03-16 Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko DK3270909T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562133739P	2015-03-16	2015-03-16
US201662277403P	2016-01-11	2016-01-11
PCT/US2016/022694 WO2016149405A1 (en)	2015-03-16	2016-03-16	Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk

Publications (1)

Publication Number	Publication Date
DK3270909T3 true DK3270909T3 (da)	2024-01-29

Family

ID=56919968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16765682.6T DK3270909T3 (da)	2015-03-16	2016-03-16	Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko

Country Status (28)

Country	Link
US (4)	US11116739B2 (da)
EP (2)	EP4327887A3 (da)
JP (4)	JP7296190B2 (da)
KR (1)	KR102662102B1 (da)
CN (3)	CN114159564A (da)
AU (2)	AU2016233257B2 (da)
BR (1)	BR112017019728A2 (da)
CA (1)	CA2978180A1 (da)
CL (1)	CL2017002334A1 (da)
DK (1)	DK3270909T3 (da)
ES (1)	ES2969489T3 (da)
FI (1)	FI3270909T3 (da)
HR (1)	HRP20240098T1 (da)
HU (1)	HUE065229T2 (da)
IL (3)	IL319610A (da)
LT (1)	LT3270909T (da)
MA (1)	MA41793A (da)
MX (2)	MX394083B (da)
PH (2)	PH12021551111A1 (da)
PL (1)	PL3270909T3 (da)
PT (1)	PT3270909T (da)
RU (1)	RU2765218C2 (da)
SG (2)	SG11201707579RA (da)
SI (1)	SI3270909T1 (da)
SM (1)	SMT202400128T1 (da)
UA (1)	UA125371C2 (da)
WO (1)	WO2016149405A1 (da)
ZA (1)	ZA201706945B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2022102472A (ru)	2015-03-13	2022-03-15	Эсперион Терапеутикс, Инк.	Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2018148417A1 (en) *	2017-02-08	2018-08-16	Esperion Therapeutics, Inc.	Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
US20180338922A1 (en) *	2017-05-26	2018-11-29	Esperion Therapeutics, Inc.	Fixed dose formulations
KR20200123181A (ko) *	2018-02-16	2020-10-28	에스페리온 테라피유틱스 인코포레이티드	뱀페도익산의 지속 방출형 제제
WO2019179494A1 (zh) *	2018-03-23	2019-09-26	深圳市塔吉瑞生物医药有限公司	取代的十五烷二酸化合物及药物组合物及其用途
US20210322376A1 (en) *	2018-08-24	2021-10-21	Esperion Therapeutics, Inc.	Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
US20210322375A1 (en) *	2018-08-27	2021-10-21	Esperion Therapeutics, Inc.	Combination drug formulations for treating patients with cardiovascular disease and associated conditions
CN112437766A (zh)	2019-06-21	2021-03-02	艾斯柏伦治疗公司	制备贝派地酸及其组合物的方法
CN113134086B (zh) *	2020-01-20	2024-05-24	深圳市长卿医学研究院	一种降血脂的药物组合物
WO2024151311A1 (en) *	2023-01-09	2024-07-18	Esperion Therapeutics, Inc.	Methods of treatment using bempedoic acid

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3152148A (en)	1963-01-03	1964-10-06	Dow Chemical Co	Preparation of comenic and pyromeconic acids
US3441605A (en)	1965-02-17	1969-04-29	Wallace & Tiernan Inc	Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
GB1196595A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Preparation of a Lactone
GB1196598A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Preparation of a Ketosebacic Acid
GB1196594A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Improvements in and relating to the production of Sebacic Acid
GB1196596A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Preparation of a hydroxysebacic acid
FR1545224A (fr)	1966-12-21	1968-11-08	Geigy Ag J R	Procédé de préparation de l'acide sébacique
US3930024A (en)	1969-09-02	1975-12-30	Parke Davis & Co	Pharmaceutical compositions and methods
US3773946A (en)	1969-09-02	1973-11-20	Parke Davis & Co	Triglyceride-lowering compositions and methods
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
US4281200A (en)	1979-08-30	1981-07-28	The Dow Chemical Company	Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en)	1979-09-04	1981-04-14	Kao Corp	Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en)	1981-12-15	1982-03-31	Yissum Res Dev Co	Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (it)	1983-05-30	1987-04-08	Luso Farmaco Inst	3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione
JPS59232811A (ja)	1983-06-16	1984-12-27	Sumitomo Chem Co Ltd	芳香族ポリアミドイミド樹脂成形体の製造方法
JPS60136512A (ja)	1983-12-26	1985-07-20	Eisai Co Ltd	脂質代謝改善剤
DE3423166A1 (de)	1984-06-22	1986-01-02	Epis S.A., Zug	Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4896344A (en)	1984-10-15	1990-01-23	Grady John K	X-ray video system
US4634119A (en)	1985-07-11	1987-01-06	Pesthy Paul K	Resilient exercise machine with body support platform
US4714762A (en)	1986-10-31	1987-12-22	Warner-Lambert Company	Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5225439A (en)	1987-01-28	1993-07-06	K.K. Ueno Seiyaku Oyo Kenkyujo	Prostaglandins E and anti ulcers containing same
US5428062A (en)	1987-01-28	1995-06-27	K.K. Ueno Seiyaku Oyo Kenkyujo	Prostaglandins E and anti ulcers containing same
US5166174A (en)	1987-01-28	1992-11-24	K.K. Ueno Seiyaku Oyo Kenkyujo	Prostaglandins E and anti-ulcers containing same
US4758880A (en)	1987-03-27	1988-07-19	The Grass Valley Group, Inc.	Video matte generator
JP2999579B2 (ja)	1990-07-18	2000-01-17	武田薬品工業株式会社	Ｄｎａおよびその用途
US5254589A (en)	1991-10-15	1993-10-19	Warner-Lambert Company	Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en)	1993-05-14	2001-01-11	Warner Lambert Co	Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5420339A (en)	1993-11-22	1995-05-30	Warner-Lambert Company	Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (ja)	1994-04-08	1999-08-23	時久増田	角筒包装袋の製造方法及び装置
US5578639A (en)	1994-07-01	1996-11-26	Warner-Lambert Company	PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5504073A (en)	1994-07-01	1996-04-02	Warner-Lambert Company	PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (sv)	1995-03-03	1995-03-03	Pharmacia Ab	Process for producing a protein
US5648387A (en)	1995-03-24	1997-07-15	Warner-Lambert Company	Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1997016184A1 (en)	1995-11-02	1997-05-09	Warner-Lambert Company	Method and pharmaceutical composition for regulating lipid concentration
US5807846A (en)	1996-11-14	1998-09-15	Warner-Lambert Company	Phosphonamide ACAT inhibitors
IL119971A (en)	1997-01-07	2003-02-12	Yissum Res Dev Co	Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en)	1997-04-21	2000-07-25	Warner-Lambert Company	N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en)	1997-06-26	1997-11-20	Yissum Res Dev Co	Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6037323A (en)	1997-09-29	2000-03-14	Jean-Louis Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en)	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
NZ503598A (en)	1997-11-25	2002-06-28	Warner Lambert Co	Hydroxylated gemfibrozil, atorvastatin and fluvastatin with antioxidant activity for inhibition of lipoprotein oxidation
HK1039487B (en)	1998-12-07	2005-08-12	Merck Sharp & Dohme Corp.	Process for the synthesis of azetidinones
US6207822B1 (en)	1998-12-07	2001-03-27	Schering Corporation	Process for the synthesis of azetidinones
MXPA01009893A (es)	1999-04-01	2003-07-28	Esperion Therapeutics Inc	Compuestos con eter, composiciones y usos de estos.
US20030180352A1 (en)	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7304093B2 (en)	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
IL155215A0 (en)	2000-10-11	2003-11-23	Esperion Therapeutics Inc	Ether compounds and compositions for cholesterol management and related uses
MXPA03003024A (es)	2000-10-11	2003-07-14	Esperion Therapeutics Inc	Compuestos de sulfoxido y bis-sulfoxido y composiciones para el control de colesterol y usos relacionados.
WO2002030860A2 (en)	2000-10-11	2002-04-18	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
AU2002211666A1 (en)	2000-10-11	2002-04-22	Esperion Therapeutics, Inc.	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7053046B2 (en)	2001-12-21	2006-05-30	Mcgrath Kevin	Peptide activators of VEGF
HUE036646T2 (hu) *	2003-01-23	2018-07-30	Esperion Therapeutics Inc	Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
DE10352659B4 (de)	2003-11-11	2007-09-13	Ratiopharm Gmbh	Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005062897A2 (en)	2003-12-23	2005-07-14	Dr. Reddy's Laboratories Ltd.	Polymorphs of ezetimibe and processes for the preparation thereof
JP2007525408A (ja)	2003-12-24	2007-09-06	エスペリオンセラピューティクス，インコーポレイテッド	コレステロール管理および関連使用のためのケトン化合物および組成物
JP4553181B2 (ja)	2004-03-25	2010-09-29	株式会社サタケ	残留農薬分析方法
US7194579B2 (en)	2004-04-26	2007-03-20	Sun Microsystems, Inc.	Sparse multi-component files
TW200803868A (en)	2005-11-15	2008-01-16	Takeda Pharmaceutical	Novel method for treating hyperlipidemia
CN101679979A (zh)	2007-03-24	2010-03-24	基酶有限公司	施用与人载脂蛋白b互补的反义寡核苷酸
EP2167069B1 (en) *	2007-05-23	2011-10-26	Amcol International Corporation	Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US8209479B2 (en)	2007-07-18	2012-06-26	Google Inc.	Memory circuit system and method
ES2639995T3 (es)	2007-12-10	2017-10-31	Ratiopharm Gmbh	Formulación farmacéutica que comprende ezetimiba
EP2168573A1 (en)	2008-09-30	2010-03-31	LEK Pharmaceuticals D.D.	Formulations comprising ezetimibe
EP2216016A1 (en)	2009-02-06	2010-08-11	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising ezetimibe
ATE536172T1 (de)	2009-03-13	2011-12-15	Sanovel Ilac Sanayi Ve Ticaret As	Ezetimibzusammensetzungen
CA2812109A1 (en)	2010-09-20	2012-03-29	Kareus Therapeutics, Sa	Methods and compositions for treatment of diabetes and dyslipidemia
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor
AR086675A1 (es)	2011-06-14	2014-01-15	Merck Sharp & Dohme	Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
US10028926B2 (en)	2012-01-06	2018-07-24	Gemphire Therapeutics Inc.	Methods of reducing risk of cardiovascular disease
CA2868416A1 (en)	2012-04-18	2013-10-24	Mallinckrodt Llc	Immediate release pharmaceutical compositions with abuse deterrent properties
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
US9527838B2 (en) *	2012-12-17	2016-12-27	Merck Sharp & Dohme Corp.	2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
RU2022102472A (ru)	2015-03-13	2022-03-15	Эсперион Терапеутикс, Инк.	Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en)	2015-08-04	2017-02-09	Dezima Pharma B.V.	Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator

2016
- 2016-03-15 MA MA041793A patent/MA41793A/fr unknown
- 2016-03-16 UA UAA201709829A patent/UA125371C2/uk unknown
- 2016-03-16 KR KR1020177029504A patent/KR102662102B1/ko active Active
- 2016-03-16 AU AU2016233257A patent/AU2016233257B2/en active Active
- 2016-03-16 SG SG11201707579RA patent/SG11201707579RA/en unknown
- 2016-03-16 IL IL319610A patent/IL319610A/en unknown
- 2016-03-16 PH PH1/2021/551111A patent/PH12021551111A1/en unknown
- 2016-03-16 PT PT167656826T patent/PT3270909T/pt unknown
- 2016-03-16 FI FIEP16765682.6T patent/FI3270909T3/fi active
- 2016-03-16 CN CN202111644578.7A patent/CN114159564A/zh active Pending
- 2016-03-16 SG SG10201908584S patent/SG10201908584SA/en unknown
- 2016-03-16 HR HRP20240098TT patent/HRP20240098T1/hr unknown
- 2016-03-16 JP JP2017549076A patent/JP7296190B2/ja active Active
- 2016-03-16 IL IL292829A patent/IL292829B2/en unknown
- 2016-03-16 DK DK16765682.6T patent/DK3270909T3/da active
- 2016-03-16 SI SI201631801T patent/SI3270909T1/sl unknown
- 2016-03-16 WO PCT/US2016/022694 patent/WO2016149405A1/en not_active Ceased
- 2016-03-16 CN CN201680015832.8A patent/CN107530308A/zh active Pending
- 2016-03-16 ES ES16765682T patent/ES2969489T3/es active Active
- 2016-03-16 HU HUE16765682A patent/HUE065229T2/hu unknown
- 2016-03-16 RU RU2017136295A patent/RU2765218C2/ru not_active Application Discontinuation
- 2016-03-16 LT LTEPPCT/US2016/022694T patent/LT3270909T/lt unknown
- 2016-03-16 BR BR112017019728A patent/BR112017019728A2/pt not_active Application Discontinuation
- 2016-03-16 CN CN202310819594.8A patent/CN116832164A/zh active Pending
- 2016-03-16 MX MX2017011500A patent/MX394083B/es unknown
- 2016-03-16 CA CA2978180A patent/CA2978180A1/en active Pending
- 2016-03-16 SM SM20240128T patent/SMT202400128T1/it unknown
- 2016-03-16 EP EP23205342.1A patent/EP4327887A3/en active Pending
- 2016-03-16 PH PH1/2017/501659A patent/PH12017501659B1/en unknown
- 2016-03-16 EP EP16765682.6A patent/EP3270909B1/en active Active
- 2016-03-16 PL PL16765682.6T patent/PL3270909T3/pl unknown
- 2016-03-16 US US15/558,519 patent/US11116739B2/en active Active
2017
- 2017-08-29 IL IL254202A patent/IL254202B/en unknown
- 2017-09-07 MX MX2022005372A patent/MX2022005372A/es unknown
- 2017-09-14 CL CL2017002334A patent/CL2017002334A1/es unknown
- 2017-10-13 ZA ZA2017/06945A patent/ZA201706945B/en unknown
2021
- 2021-03-01 JP JP2021031891A patent/JP2021102615A/ja active Pending
- 2021-08-27 AU AU2021221908A patent/AU2021221908A1/en not_active Abandoned
- 2021-09-02 US US17/465,354 patent/US20220110904A1/en not_active Abandoned
2023
- 2023-02-27 JP JP2023028113A patent/JP2023062198A/ja active Pending
- 2023-05-31 US US18/326,636 patent/US20240148681A1/en not_active Abandoned
2024
- 2024-11-15 US US18/949,376 patent/US20250064767A1/en active Pending
2025
- 2025-12-01 JP JP2025210935A patent/JP2026041848A/ja active Pending

Also Published As

Publication number	Publication date
MA41793A (fr)	2018-01-23
EP4327887A2 (en)	2024-02-28
PH12017501659A1 (en)	2018-03-12
CA2978180A1 (en)	2016-09-22
AU2021221908A1 (en)	2021-09-23
IL292829B1 (en)	2025-04-01
ZA201706945B (en)	2022-02-23
IL319610A (en)	2025-05-01
EP3270909A4 (en)	2018-08-01
HUE065229T2 (hu)	2024-05-28
US20220110904A1 (en)	2022-04-14
KR20180006889A (ko)	2018-01-19
SG11201707579RA (en)	2017-10-30
CN116832164A (zh)	2023-10-03
EP3270909A1 (en)	2018-01-24
MX394083B (es)	2025-03-24
LT3270909T (lt)	2024-02-26
EP3270909B1 (en)	2023-11-01
HRP20240098T1 (hr)	2024-04-12
BR112017019728A2 (pt)	2018-05-22
JP2021102615A (ja)	2021-07-15
MX2017011500A (es)	2018-03-26
MX2022005372A (es)	2022-05-19
US20180078518A1 (en)	2018-03-22
WO2016149405A1 (en)	2016-09-22
RU2017136295A3 (da)	2019-07-17
IL254202A0 (en)	2017-10-31
PT3270909T (pt)	2024-02-05
PH12021551111A1 (en)	2023-07-17
US20250064767A1 (en)	2025-02-27
EP4327887A3 (en)	2024-05-15
JP2018508551A (ja)	2018-03-29
US20240148681A1 (en)	2024-05-09
JP7296190B2 (ja)	2023-06-22
US11116739B2 (en)	2021-09-14
SMT202400128T1 (it)	2024-05-14
SG10201908584SA (en)	2019-11-28
ES2969489T3 (es)	2024-05-20
AU2016233257B2 (en)	2021-05-27
RU2765218C2 (ru)	2022-01-26
IL292829B2 (en)	2025-08-01
KR102662102B1 (ko)	2024-05-02
PH12017501659B1 (en)	2023-01-11
PL3270909T3 (pl)	2024-05-13
IL292829A (en)	2022-07-01
CN114159564A (zh)	2022-03-11
IL254202B (en)	2022-06-01
FI3270909T3 (fi)	2024-02-01
JP2023062198A (ja)	2023-05-02
JP2026041848A (ja)	2026-03-10
HK1245643A1 (en)	2018-08-31
NZ735168A (en)	2024-07-05
UA125371C2 (uk)	2022-03-02
SI3270909T1 (sl)	2024-03-29
AU2016233257A1 (en)	2017-11-02
CN107530308A (zh)	2018-01-02
CL2017002334A1 (es)	2018-03-16
RU2017136295A (ru)	2019-04-16

Publication	Publication Date	Title
DK3270909T3 (da)	2024-01-29	Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko
DK3445388T3 (da)	2024-06-03	Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3322804T3 (da)	2021-10-04	Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3387134T3 (da)	2020-12-21	Fremgangsmåder og sammensætninger til øget nukleasemedieret genommodifikation og reducerede virkninger uden for målstedet
DK3368534T3 (da)	2021-02-15	Valbenazin-ditosylat og polymorfer deraf
DK3402499T3 (da)	2021-09-27	Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3265947T3 (da)	2021-10-04	Fremgangsmåde og system til kryptering
DK3259597T3 (da)	2022-05-09	Pvrig-polypeptider og fremgangsmåder til behandling
DK3277270T3 (da)	2021-12-06	Sammensætninger og fremgangsmåder til behandling af anæmi
DK3212189T3 (da)	2020-10-26	Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3242947T3 (da)	2020-08-03	Genterapi og elektroporese til behandling af maligniteter
FIC20260013I1 (fi)	2026-04-20	ikodekinsuliini ja semaglutidi
DK3189074T3 (da)	2021-04-19	Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3481846T3 (da)	2021-08-16	11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3178324T3 (da)	2020-11-23	Mikrobicid og fremgangsmåde til fremstilling af samme
DK3347014T3 (da)	2021-12-06	Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom
DK3328864T3 (da)	2022-12-05	Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3393655T3 (da)	2021-03-15	Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3265641T3 (da)	2020-03-16	Stigørenhed og fremgangsmåde
DK3367852T3 (da)	2019-12-16	Indretning og fremgangsmåde til behandling af levnedsmidler
DK3174559T3 (da)	2022-12-05	Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer
DK3310190T3 (da)	2020-08-24	Sammensætning til behandling af kød og anvendelse af denne
DK3315181T3 (da)	2021-05-31	Sammensat emne og fremgangsmåde til at fremstille samme
DK3522873T3 (da)	2022-06-20	Sammensætninger og fremgangsmåder til behandlingen af xerostomi